JP2020502147A5 - - Google Patents

Download PDF

Info

Publication number
JP2020502147A5
JP2020502147A5 JP2019531988A JP2019531988A JP2020502147A5 JP 2020502147 A5 JP2020502147 A5 JP 2020502147A5 JP 2019531988 A JP2019531988 A JP 2019531988A JP 2019531988 A JP2019531988 A JP 2019531988A JP 2020502147 A5 JP2020502147 A5 JP 2020502147A5
Authority
JP
Japan
Prior art keywords
seq
nos
antibody
cdr
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019531988A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020502147A (ja
JP7252627B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/066815 external-priority patent/WO2018112407A1/en
Publication of JP2020502147A publication Critical patent/JP2020502147A/ja
Publication of JP2020502147A5 publication Critical patent/JP2020502147A5/ja
Priority to JP2022189027A priority Critical patent/JP2023026426A/ja
Application granted granted Critical
Publication of JP7252627B2 publication Critical patent/JP7252627B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019531988A 2016-12-15 2017-12-15 制御性ｂ１０細胞を枯渇させる抗体および方法並びに免疫チェックポイント阻害剤との併用における使用 Active JP7252627B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022189027A JP2023026426A (ja) 2016-12-15 2022-11-28 制御性ｂ１０細胞を枯渇させる抗体および方法並びに免疫チェックポイント阻害剤との併用における使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662434833P 2016-12-15 2016-12-15
US62/434,833 2016-12-15
PCT/US2017/066815 WO2018112407A1 (en) 2016-12-15 2017-12-15 Antibodies and methods for depleting regulatory b10 cells and use in combination with immune checkpoint inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022189027A Division JP2023026426A (ja) 2016-12-15 2022-11-28 制御性ｂ１０細胞を枯渇させる抗体および方法並びに免疫チェックポイント阻害剤との併用における使用

Publications (3)

Publication Number Publication Date
JP2020502147A JP2020502147A (ja) 2020-01-23
JP2020502147A5 true JP2020502147A5 (enExample) 2021-02-04
JP7252627B2 JP7252627B2 (ja) 2023-04-05

Family

ID=62559412

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019531988A Active JP7252627B2 (ja) 2016-12-15 2017-12-15 制御性ｂ１０細胞を枯渇させる抗体および方法並びに免疫チェックポイント阻害剤との併用における使用
JP2022189027A Pending JP2023026426A (ja) 2016-12-15 2022-11-28 制御性ｂ１０細胞を枯渇させる抗体および方法並びに免疫チェックポイント阻害剤との併用における使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022189027A Pending JP2023026426A (ja) 2016-12-15 2022-11-28 制御性ｂ１０細胞を枯渇させる抗体および方法並びに免疫チェックポイント阻害剤との併用における使用

Country Status (5)

Country Link
US (1) US11230598B2 (enExample)
EP (1) EP3554515A4 (enExample)
JP (2) JP7252627B2 (enExample)
CN (1) CN110248668B (enExample)
WO (1) WO2018112407A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201412658D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
GB201601075D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies molecules
GB201601077D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibody molecule
GB201601073D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies
CN110248668B (zh) * 2016-12-15 2023-05-30 杜克大学 用于消耗调节性b10细胞的抗体和方法以及与免疫检查点抑制剂的联用
CN112368273A (zh) 2018-06-25 2021-02-12 正大天晴药业集团股份有限公司 喹啉衍生物的晶习及其结晶粉末的制备方法
CN113874400B (zh) * 2019-03-11 2025-02-07 詹森生物科技公司 抗Vβ17/抗CD123双特异性抗体
CN114901310A (zh) * 2019-12-24 2022-08-12 尼尔路金治疗公司 使用il-2受体激动剂和免疫检查点抑制剂的组合疗法
EP4204008A1 (en) * 2020-08-26 2023-07-05 Citius Pharmaceuticals, Inc. Combination for use in methods of treating cancer
AU2021339754A1 (en) 2020-09-11 2023-05-25 Janssen Biotech, Inc. Methods and compositions for modulating beta chain mediated immunity
CN116568811A (zh) * 2021-01-13 2023-08-08 上海华奥泰生物药业股份有限公司 结合cd73的蛋白及其应用
US20260116991A1 (en) * 2021-02-03 2026-04-30 Hainan Simcere Zaiming Pharmaceutical Co., Ltd. Monoclonal antibody for specifically recognizing glypican-3, and application thereof

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5298614A (en) 1986-01-06 1994-03-29 Nippon Shinyaku Co. Ltd. Size limited double stranded poly I poly(cytidylate/4-thiouridylate)
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5484892A (en) 1993-05-21 1996-01-16 Dana-Farber Cancer Institute, Inc. Monoclonal antibodies that block ligand binding to the CD22 receptor in mature B cells
AU3272695A (en) 1994-08-12 1996-03-07 Immunomedics Inc. Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells
ATE267610T1 (de) 1996-03-20 2004-06-15 Immunomedics Inc Glykosylierte igg antikörper
US6183744B1 (en) 1997-03-24 2001-02-06 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
CN1194002C (zh) 1999-02-15 2005-03-23 日本新药株式会社 短链化多核苷酸及其制备方法
WO2001097843A2 (en) 2000-06-22 2001-12-27 University Of Iowa Research Foundation Methods for enhancing antibody-induced cell lysis and treating cancer
AU2001273009A1 (en) 2000-06-26 2002-01-08 Maxygen, Inc. Methods and compositions for developing spore display systems for medicinal and industrial applications
DE60334364D1 (de) 2002-02-21 2010-11-11 Univ California Behandlungsverfahren unter verwendung von anti-cd22-antikörpern
CA2497628A1 (en) 2002-09-05 2004-03-18 Medimmune, Inc. Methods of preventing or treating cell malignancies by administering cd2 antagonists
EP1578397B1 (en) 2002-11-15 2012-12-26 Genmab A/S Human monoclonal antibodies against cd25
WO2004053057A2 (en) 2002-12-11 2004-06-24 3M Innovative Properties Company Gene expression systems and recombinant cell lines
WO2004053452A2 (en) 2002-12-11 2004-06-24 3M Innovative Properties Company Assays relating to toll-like receptor activity
WO2004094671A2 (en) 2003-04-22 2004-11-04 Coley Pharmaceutical Gmbh Methods and products for identification and assessment of tlr ligands
KR101351122B1 (ko) 2003-05-09 2014-01-14 듀크 유니버시티 Ｃｄ２０-특이적 항체 및 이를 이용한 방법
WO2006050155A2 (en) 2004-10-29 2006-05-11 Biomune, Inc. Cancer therapeutic compositions
CA2587676A1 (en) 2004-11-19 2006-05-26 Institut Gustave Roussy Improved treatment of cancer by double-stranded rna
AU2006244445B2 (en) 2005-05-05 2013-04-18 Duke University Anti-CD19 antibody therapy for autoimmune disease
EP1998799B8 (en) 2006-03-06 2014-03-05 Medlmmune, LLC Humanized anti-cd22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
CN103044550A (zh) * 2006-09-01 2013-04-17 津莫吉尼蒂克斯公司 Il-31单克隆抗体的可变区序列和使用方法
RU2448729C2 (ru) 2006-09-01 2012-04-27 Жантисель Композиции, вызывающие специфический ответ цитотоксических т-лимфоцитов, включающие лимфо-аблативное соединение и молекулу, содержащую антигенные последовательности и нацеленную на специализированные антиген-презентирующие клетки
US20090074711A1 (en) 2006-09-07 2009-03-19 University Of Southhampton Human therapies using chimeric agonistic anti-human cd40 antibody
AU2007317333A1 (en) 2006-11-02 2008-05-15 Seattle Genetics, Inc. Methods of treating neoplastic, autoimmune and inflammatory diseases
CA2695385A1 (en) 2007-07-31 2009-02-05 Atul Bedi Polypeptide-nucleic acid conjugate for immunoprophylaxis or immunotherapy for neoplastic or infectious disorders
EP2242836B1 (en) 2008-01-28 2015-05-20 Thomas Jefferson University Method of making hybrid cells that express useful antibodies
WO2009131712A2 (en) * 2008-04-25 2009-10-29 Duke University Medical Center Regulatory b cells and their uses
EP3683317A3 (en) 2009-05-13 2020-09-30 Genzyme Corporation Anti-human cd52 immunoglobulins
ES2434256T3 (es) 2010-05-28 2013-12-16 F. Hoffmann-La Roche Ag Método de cultivo de células B individuales y producción de anticuerpos específicos
NZ772688A (en) 2010-06-03 2022-09-30 Pharmacyclics Llc The use of inhibitors of bruton’s tyrosine kinase (btk)
US10131875B2 (en) * 2010-08-04 2018-11-20 Duke University Regulatory B cells and their uses
US9814740B2 (en) 2010-12-21 2017-11-14 Duke University Methods and compositions combining immunotherapy with monocyte activation
US20140212425A1 (en) * 2011-12-05 2014-07-31 Immunomedics, Inc. Therapeutic use of anti-cd22 antibodies for inducing trogocytosis
US10017739B2 (en) 2012-09-06 2018-07-10 Duke University Methods of expanding and assessing B cells and using expanded B cells to treat disease
TWI595006B (zh) * 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
MX2017012939A (es) * 2015-04-08 2018-05-22 Novartis Ag Terapias cd20, terapias cd22 y terapias de combinacion con una celula que expresa un receptor quimerico de antigeno (car) de cd19.
CN110248668B (zh) * 2016-12-15 2023-05-30 杜克大学 用于消耗调节性b10细胞的抗体和方法以及与免疫检查点抑制剂的联用

Similar Documents

Publication Publication Date Title
JP2021527431A5 (enExample)
JP2019500892A5 (enExample)
FI3823664T3 (fi) Bispesifisiä anti-BCMA- x anti-CD3-vasta-aineita ja niiden käyttöjä
JP2022515611A5 (enExample)
JP2019513725A5 (enExample)
JP2019500891A5 (enExample)
JP2022507295A5 (enExample)
JP2021531005A5 (enExample)
CN110248668B (zh) 用于消耗调节性b10细胞的抗体和方法以及与免疫检查点抑制剂的联用
RU2016131170A (ru) Способы и композиции для лечения персистирующих инфекций
JP2019529373A5 (ja) 抗Ｔｉｍ−３抗体
JP2016533763A5 (ja) ヒトｐｄ−１に特異的に結合する抗体抗原結合ドメインおよびそれを含む医薬組成物
RU2016107426A (ru) Комбинирование агонистов cd27 и ингибирование иммунных контрольных точек для стимуляции иммунитета
RU2018135247A (ru) БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА К CD25 И Fc ГАММА-РЕЦЕПТОРУ ДЛЯ ЭЛИМИНАЦИИ ОПУХОЛЕСПЕЦИФИЧЕСКИХ КЛЕТОК
HRP20231156T1 (hr) Kombinacija anti-pd-1 antitijela i bispecifičnih anti-cd20/anti-cd3 antitijela za liječenje raka
JP2017535257A5 (enExample)
IL318482A (en) Pd-1 inhibitor for use in a method of treating skin cancer
PH12020551173A1 (en) Anti-pd-l1 antibodies and uses thereof
RU2021121771A (ru) Cd20 терапия, cd22 терапия и комбинированная терапия клетками, экспрессирующими химерный антигенный рецептор (car) к cd19
JP2018035138A5 (enExample)
RU2018126297A (ru) Антитела, нацеленные на cd32b, и способы их применения
RU2017105118A (ru) Нейтрализация ингибирующих путей в лимфоцитах
IL299221A (en) Cd3 binding antibodies
JP2016531907A5 (enExample)
JP2017501157A5 (enExample)